Asthma management is evolving, and the latest guidelines are transforming how we approach treatment and long-term care. But are these changes universally beneficial? This article delves into the updated recommendations for asthma management, offering a comprehensive overview for healthcare professionals.
For patients aged 12 and above, the traditional advice of carrying a blue inhaler is being replaced. Instead, the new guidelines suggest offering Anti-Inflammatory Relief (AIR) therapy with a formoterol-containing inhaled steroid inhaler for those newly diagnosed. This approach is recommended for asymptomatic individuals at the time of presentation. However, here's a twist: if a patient is unwell or exacerbating, a different strategy is needed.
In such cases, a low-dose Maintenance and Reliever Therapy (MART) is advised, using a single combination inhaler instead of separate preventer and reliever inhalers. If symptoms persist, a moderate-dose MART regime is the next step. But what if this doesn't work? It's crucial to assess adherence, inhaler technique, and new triggers. And this is where it gets intriguing: the cause of symptoms might be uncontrolled eosinophilic airway inflammation or bronchospasm.
A FeNO test (measuring fractional exhaled nitric oxide) can help determine the next steps. If the FeNO level is raised, a specialist referral is required. Otherwise, a Long-Acting Muscarinic Antagonist (LAMA) or Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose MART regimen for 8-12 weeks is recommended. The treatment plan is then adjusted based on symptom improvement.
For patients with an existing asthma diagnosis, the previous treatment is still valid if asthma is controlled and salbutamol use is minimal. However, those relying solely on salbutamol may benefit from an AIR regime. Patients on low-dose inhaled steroids who become symptomatic should switch to a low-dose MART, and those on moderate-dose steroids should move to a moderate-dose MART.
In children aged 5-11, MART is advised despite the lack of licensed inhalers. This can be prescribed off-label, but it's important to document this in line with NICE/BTS/SIGN guidelines. For children under 5, the focus is on the Quality and Outcomes Framework (QOF), which now requires specific tests for a correct diagnosis.
Monitoring asthma involves asking key questions at reviews: Is asthma affecting school or work attendance? How much reliever inhaler is being used? How often are oral corticosteroids needed? Are there emergency visits or hospital admissions? The guidelines recommend an asthma control test, and FeNO testing for adults before and after medication changes.
If asthma control is poor, checking FeNO levels is crucial. A Short-Acting Beta2 Agonist (SABA) should not be prescribed without an Inhaled Corticosteroid (ICS), and medication changes should be reviewed within 8-12 weeks. When changing medication, factors like inhaler technique, patient preference, and environmental impact are considered.
Healthcare professionals are encouraged to identify high-risk asthma patients, focusing on non-adherence, SABA overuse, corticosteroid use, and hospital admissions. But a controversial point: while evaluating high-risk patients is essential, it's equally important not to neglect the rest.
These guidelines from NICE, BTS, and SIGN significantly impact asthma diagnosis and management. While adapting to these changes may be challenging, education and resources are vital for successful implementation. This unified approach promises improved asthma care and better outcomes for patients.
About Bedfont® Scientific Ltd: Specializing in exhaled breath and gas monitoring since 1976, Bedfont® offers innovative solutions. Their Medi-Gas Check range ensures medical gas quality, while breath analyzers like Smokerlyzer® and ToxCO® aid in smoking cessation and CO poisoning diagnosis. The NObreath® FeNO monitor and Gastrolyzer® range further enhance asthma control and gastrointestinal disorder detection. Sponsored by Bedfont® Scientific, this content aims to educate healthcare professionals on the latest asthma management guidelines.
